Drug Trial Radar · NCT03478891
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Last checked: Nov 20, 2026Latest source record: Oct 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
May 16, 2018
Primary completion
Mar 20, 2019
Study completion Mar 20, 2019
Sponsor
- Sponsor type
- NIH
- First posted
- Mar 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: Ebola is a virus that has infected and killed people mostly in West Africa. There is no treatment or prevention for it, but several drugs are being studied. Researchers want to test the drug MAb114 in healthy people not exposed to Ebola to see whether it can be used for Ebola treatment in people who are infected in the future. This trial will not expose volunteers to the Ebola virus. Objectives: To see if MAb114 is safe and how a person's body responds to it. Eligibility: Healthy adults ages 18-60 who weigh 220.5 pounds or less Design: Participants will be screened under protocol NIH 11-I-0164 with: * Medical history * Physical exam * Blood or urine tests Participants will have a first 8- to10-hour visit. They will get MAb114 by IV infusion. For this, a thin tube will be placed in an arm vein. They may get an IV line in their other arm to collect blood. Blood will be taken many times before and after the infusion. Participants may have a urine test. Participants will get a thermometer to check their temperature for 3 days after they get MAb114. They will record their highest temperature and any symptoms. Participants will have about 14 more study visits over 6 months. At each visit, they will have blood taken and be checked for any health changes. They will talk about how they are feeling and if they have taken any medications. At the end of the 6 months, participants may be invited to take part in another study for follow-up sample collection.
Conditions
- Healthy Adult Immune Responses to Vaccine
Interventions
VRC-EBOMAB092-00-AB (MAb114)Biological
VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Experiencing Infusion Reaction During Product AdministrationTime frame: About 30 minutes of product administration
- Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Product AdministrationTime frame: 3 days after product administration
- Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product AdministrationTime frame: 7 days after product administration
- Number of Subjects Reporting 1 or More Unsolicited Non-Serious Adverse EventsTime frame: Through 24 weeks after product administration
- Number of Subjects Reporting Serious Adverse EventsTime frame: Through 24 weeks after product administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.